Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Share-based Compensation (2016 - 2025)

Enanta Pharmaceuticals filings provide 14 years of Share-based Compensation readings, the most recent being $3.8 million for Q4 2025.

  • On a quarterly basis, Share-based Compensation fell 32.76% to $3.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $16.7 million, a 31.41% decrease, with the full-year FY2025 number at $18.6 million, down 30.71% from a year prior.
  • Share-based Compensation hit $3.8 million in Q4 2025 for Enanta Pharmaceuticals, down from $4.0 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $8.1 million in Q4 2023 to a low of $3.8 million in Q4 2025.
  • Median Share-based Compensation over the past 5 years was $5.9 million (2021), compared with a mean of $6.0 million.
  • Biggest five-year swings in Share-based Compensation: soared 38.87% in 2022 and later plummeted 47.73% in 2025.
  • Enanta Pharmaceuticals' Share-based Compensation stood at $6.1 million in 2021, then increased by 17.77% to $7.1 million in 2022, then increased by 13.45% to $8.1 million in 2023, then plummeted by 30.04% to $5.7 million in 2024, then crashed by 32.76% to $3.8 million in 2025.
  • The last three reported values for Share-based Compensation were $3.8 million (Q4 2025), $4.0 million (Q3 2025), and $4.2 million (Q2 2025) per Business Quant data.